Company news
Anavex Life Sciences Corp. news in 2023
Anavex Life Sciences Corp.'s news releases, calls and decks from 2023, newest first.
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
December 19, 2023
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
December 18, 2023
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
November 26, 2023
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
November 23, 2023
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety
November 21, 2023
Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)
November 19, 2023
Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
November 5, 2023
Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease
October 24, 2023
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
September 13, 2023
Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board
September 11, 2023
Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results
August 7, 2023
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety
August 6, 2023
Anavex Life Sciences to Present at the BTIG Virtual Biotechnology Conference 2023
August 1, 2023
Anavex Life Sciences to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023
July 31, 2023
Long-term Clinical Study Demonstrates Disease Modifying Effects of ANAVEX®2-73 (blarcamesine) for Rett Syndrome
June 27, 2023
Anavex Life Sciences and Partex Group Announce Strategic Partnership to Leverage AI for Drug Development and Healthcare Sales Marketing Building a Patient-Centric Digital Ecosystem
June 26, 2023
Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
June 19, 2023
ANAVEX®2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients with Rett Syndrome
June 14, 2023
Anavex Life Sciences Reports Publication in Medical Journal Signifying Continued Commitment for Improvement of the Rett Syndrome Caregiver Outcome Measure RSBQ
June 11, 2023
Anavex Life Sciences Announces Completion of ANAVEX(®)2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
June 5, 2023
ANAVEX Announces Issuance of New U.S. Intellectual Property Compositions Patent for ANAVEX®2-73 (blarcamesine)
May 31, 2023
Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results
May 8, 2023
Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Results on Tuesday, May 9, 2023
May 1, 2023
Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension
April 30, 2023
Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 24, 2023
Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
April 9, 2023
ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
March 29, 2023
Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of Biostatistics
March 8, 2023
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
February 6, 2023
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
February 1, 2023
Anavex Life Sciences to Announce Fiscal 2023 First Quarter Financial Results on Tuesday February 7, 2023
January 30, 2023
Calls in 2023
- Anavex Life Sciences (NASDAQ:AVXL) Q4 2023 Earnings Call
Nov 27, 2023
Transcript - Anavex Life Sciences (NASDAQ:AVXL) Q3 2023 Earnings Call
Aug 8, 2023
Transcript - Anavex Life Sciences (NASDAQ:AVXL) Q2 2023 Earnings Call
May 9, 2023
Transcript - Anavex Life Sciences (NASDAQ:AVXL) Q1 2023 Earnings Call
Feb 7, 2023
Transcript